Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in ESKD - A Feasibility Study
NCT05687058Phase 2Active, not recruiting
- Sponsor
- University of Mississippi Medical Center
- Start
- Nov 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in end-stage kidney disease (ESKD), heart failure (HF), sponsored by University of Mississippi Medical Center. Started Nov 2023; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
end-stage kidney disease (ESKD)heart failure (HF)
Beyond the preview
Go deeper on NCT05687058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05687058.